The present invention relates to a process for the preparation of (R) -methyl-2- (3-aminopiperidin- 1 -yl) -3- (2-cyanobenzyl) -4-carbonyl- 2-d] pyrimidine-6-carboxylic acid ((R) -Methyl-2- (3-aminopiperidin-1-yl) -3- (2-cyanobenzyl) -4-carbonyl-3,4-dihydrothiophene , 2-d] pyrimidine-6-carboxylic acid, and a process for their preparation. The present invention also discloses a pharmaceutical composition in the form of a compound salt of Formula I above. The salt form of the present invention has a relatively strong in vivo hypolipidemic activity and is expected to be a novel active ingredient of a drug that treats or prevents the complications of type II diabetes and / or type II diabetes.본 발명은 (R)-메틸-2-(3-아미노피페리딘-1-일)-3-(2-시아노벤질)-4-카르보닐-3,4-디히드로티오펜[3,2-d]피리미딘-6-카르복실산((R)-Methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene [3,2-d] Pyrimidine-6-carboxylic acid)의 염 형태 및 이의 제조 방법에 관한 것이다. 본 발명은 또한 상기 식I의 화합물 염 형태의 약물 조성물을 개시하였다. 본 발명의 염 형태는 비교적 강력한 체내 당 강하 활성이 있으며, II형 당뇨병 및/또는 II형 당뇨병의 합병증을 치료 또는 예방하는 약물의 신규한 활성 성분으로 기대된다.
